Inovio CEO receives stock options and RSUs grant

INOVIO PHARMACEUTICALS, INC.

Rhea-AI Filing Summary

INOVIO PHARMACEUTICALS, INC. Chief Executive Officer Jacqueline Elizabeth Shea reported equity awards consisting of stock options and restricted stock units. On March 4, 2026, she acquired 97,240 stock options and 78,760 restricted stock units as grants, each at a price of $0.00 per unit.

According to the vesting schedule, 32,414 of the options vest on February 26, 2027, 32,413 on February 26, 2028, and 32,413 on February 26, 2029. For the 78,760 restricted stock units, 26,254 vest on February 26, 2027, 26,253 on February 26, 2028, and 26,253 on February 26, 2029, with each unit representing a right to one share of common stock, settleable in stock, cash, or a combination.

Insider Trade Summary

Grant/Award: 176,000 shares

Grant/Award 2 txns

Insider Shea Jacqueline Elizabeth

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock Option	97,240	$0.00	$0.00
Grant/Award	Restricted Stock Unit	78,760	$0.00	$0.00

Holdings After Transaction: Common Stock Option — 97,240 contracts (Direct); Restricted Stock Unit — 78,760 contracts (Direct)

Footnotes (2)

1. F1. The vesting schedule for the 97,240 options granted on March 4, 2026 was as follows: 32,414 shares will vest on February 26, 2027; 32,413 shares will vest on February 26, 2028; 32,413 shares will vest on February 26, 2029.
2. F2. Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 78,760 restricted stock units granted on March 4, 2026 was as follows: 26,254 shares will vest on February 26, 2027; 26,253 shares will vest on February 26, 2028; and 26,253 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

FAQ

What did INO CEO Jacqueline Shea report in this Form 4 filing?

She reported equity awards granted on March 4, 2026, including 97,240 stock options and 78,760 restricted stock units. These awards are part of her compensation and vest over three years, potentially increasing her future share-based interest in INOVIO PHARMACEUTICALS.

How many stock options were granted to INO CEO Jacqueline Shea?

She received 97,240 stock options at a price of $0.00 per option. The options vest in three tranches: 32,414 options on February 26, 2027, 32,413 on February 26, 2028, and 32,413 on February 26, 2029, subject to continued service conditions.

What restricted stock units (RSUs) were granted to the INO CEO?

Jacqueline Shea was granted 78,760 restricted stock units on March 4, 2026. Each RSU represents a contingent right to receive one share of INOVIO common stock and vests in three annual installments through February 26, 2029, if vesting conditions are satisfied.

What is the vesting schedule for Jacqueline Shea’s INO stock options?

The 97,240 options vest in three annual installments: 32,414 shares on February 26, 2027, 32,413 shares on February 26, 2028, and 32,413 shares on February 26, 2029. This structure ties potential option value to multi-year service and performance.

How do the INO CEO’s restricted stock units vest and settle?

The 78,760 restricted stock units vest in three tranches: 26,254 on February 26, 2027, 26,253 on February 26, 2028, and 26,253 on February 26, 2029. Once vested, they may be settled in INOVIO common stock, cash, or a combination, as permitted.

Does this INO Form 4 show any insider share sales by the CEO?

No, this Form 4 reflects only grant or award acquisitions of equity incentives, not sales. It records the issuance of stock options and restricted stock units to the CEO, with no reported disposals or open-market transactions in INOVIO shares in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 04:55 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shea Jacqueline Elizabeth

(Last) (First) (Middle)

660 W. GERMANTOWN PIKE

(Street)

PLYMOUTH MEETING PA 19462

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INOVIO PHARMACEUTICALS, INC. [ INO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock Option	$1.73	03/04/2026		A		97,240		(1)	02/26/2036	Common Stock	97,240	$0	97,240	D
Restricted Stock Unit	(2)	03/04/2026		A		78,760		(2)	(2)	Common Stock	78,760	$0	78,760	D

Explanation of Responses:

1. The vesting schedule for the 97,240 options granted on March 4, 2026 was as follows: 32,414 shares will vest on February 26, 2027; 32,413 shares will vest on February 26, 2028; 32,413 shares will vest on February 26, 2029.

2. Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 78,760 restricted stock units granted on March 4, 2026 was as follows: 26,254 shares will vest on February 26, 2027; 26,253 shares will vest on February 26, 2028; and 26,253 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Remarks:

	/s/ Jacqueline E. Shea	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.